10 months after first mega round, Glick's Odyssey raises $168M to gear up for entering clinic

The Odyssey Therapeutics story is progressing quickly. Ten months after disclosing a $218 million series A, the Gary Glick-helmed biotech is back with another mega round as it prepares to push candidates into clinic-enabling studies next year.